Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.50 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: apilimod, apilimod mesylate | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 10 Parkinson's papers of 434 | 0.69 |
| pathways Reactome | 3 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 0234
Sealed predictions
- PIKFYVE in dopamine neurons, braak+0.12 (p 0.753) → +0.21 (p 0.586)receipt 0240
Swarm cases
receipt 0240: PIKFYVE in dopamine neurons, braak
- power
- full sample +0.19 (p 0.460, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.14 (p 0.591, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.18 (p 0.482, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.33, sign flips 0; without severely affected donors +0.19 (p 0.460, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.77 (p 1.8e-4, n 18) vs +0.19 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PIKFYVE in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PIKFYVE · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.68 p 0.016 (needs p < 0.0019)
Receipts
loading the receipts